Aptus Capital Advisors
EPRX icon

Aptus Capital Advisors’s Eupraxia Pharmaceuticals EPRX Stock Holding History

Aptus Capital Advisors’s Portfolio EPRX Stock Details EPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$69.4K Hold
10,500
– – ﹤0.01% 1330
2026
Q1 		$76K Buy
10,500
+500
+5% +$4.02K ﹤0.01% 1205
2025
Q4 		$75.5K Buy
+10,000
New +$61.6K ﹤0.01% 1227

Other funds holding EPRX

Beutel, Goodman & Co
Beutel, Goodman & Co Toronto, Ontario, Canada $13.6B AUM 17.82% 1-Year Est. Return
Affinity Asset Advisors
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Vivo Capital
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Scotia Capital
Scotia Capital Toronto, Ontario, Canada $26.8B AUM 33.07% 1-Year Est. Return
PFM Health Sciences
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
Great Point Partners
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
Jupiter Topco
Jupiter Topco New York $245B AUM
Rubric Capital Management (New York)
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Ikarian Capital
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

Aptus Capital Advisors's EPRX Position: Q2 2026 in Review

Aptus Capital Advisors held its Eupraxia Pharmaceuticals (EPRX) position steady in Q2 2026 at 10,500 shares worth $69.4K. The position accounts for ﹤0.01% of the portfolio, ranked #1330.

Aptus Capital Advisors first reported a position in EPRX in Q4 2025 and has held it in 3 quarters since. The position peaked at $76K in Q1 2026. 67 funds tracked by Wall St. Rank hold EPRX as of Q2 2026.

  • Aptus Capital Advisors held 10,500 shares of Eupraxia Pharmaceuticals worth $69.4K as of Q2 2026.
  • Aptus Capital Advisors left its Eupraxia Pharmaceuticals share count unchanged in Q2 2026.
  • Eupraxia Pharmaceuticals made up ﹤0.01% of Aptus Capital Advisors's portfolio in Q2 2026, its #1330 holding.
  • Aptus Capital Advisors first reported a position in Eupraxia Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • Aptus Capital Advisors's Eupraxia Pharmaceuticals position peaked at $76K in Q1 2026.
  • 67 funds tracked by Wall St. Rank held Eupraxia Pharmaceuticals as of Q2 2026.

Based on Aptus Capital Advisors's 13F filing for Q2 2026, filed 12 Aug 2026.